Standards of care and novel approaches in the management of glioblastoma multiforme.
- Author:
Andreas F HOTTINGER
1
;
Roger STUPP
;
Krisztian HOMICSKO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Angiogenesis Inhibitors; therapeutic use; Antibodies, Monoclonal, Humanized; therapeutic use; Bevacizumab; Brain Neoplasms; therapy; Cancer Vaccines; therapeutic use; Electric Stimulation Therapy; Glioblastoma; therapy; Humans; Immunotherapy; Quinazolines; therapeutic use; Receptor, Epidermal Growth Factor; antagonists & inhibitors; Snake Venoms; therapeutic use; Standard of Care; Vaccines, Subunit; therapeutic use
- From:Chinese Journal of Cancer 2014;33(1):32-39
- CountryChina
- Language:English
- Abstract: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Standard therapeutic approaches provide modest improvement in the progression-free and overall survival, necessitating the investigation of novel therapies. We review the standard treatment options for GBM and evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.
